Informations générales (source: ClinicalTrials.gov)
Could Psycho-bio-social Context and Personality be a Predictive Factor of Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease Patients? - PERSO-PERF Study (PERSO-PERF)
Observational
University Hospital, Toulouse (Voir sur ClinicalTrials)
février 2024
avril 2026
30 août 2024
Since our previous study has shown that some personality dimensions were associated with
Quality of Life (QoL) amelioration after Deep Brain Stimulation (DBS) in Parkinson's
disease (PD), the investigators aim to evaluate the impact of personality dimensions on
therapeutic response after another second-line treatment: the continuous subcutaneous
apomorphine infusion (CSAI). Moreover, the investigators would like to evaluate the
potential evolution of personality dimensions through CSAI. The investigators also aim to
evaluate other bio-psycho-social factors (representations of the disease, ways of copying
and social support) influence on QoL amelioration after DBS.
Etablissements
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
---|---|---|---|---|---|
Chu de Grenoble - Grenoble - France | ELENA MORO | Contact (sur clinicalTrials) | |||
Chu de Lyon - Bron - France | STEPHANE THOBOIS | Contact (sur clinicalTrials) | |||
Chu de Nancy - Nancy - France | SOLENE FRISMAND | Contact (sur clinicalTrials) | |||
Chu de Nice - Nice - France | CAROLINE GIORDANA | Contact (sur clinicalTrials) | |||
Chu de Poitiers - Poitiers - France | ISABELLE BENATRU | Contact (sur clinicalTrials) | |||
Chu de Rennes - Rennes - France | SOPHIE DRAPIER | Contact (sur clinicalTrials) | |||
Chu de Rouen - Rouen - France | DAVID MALTETE | Contact (sur clinicalTrials) | |||
Chu de Toulouse - Toulouse - France | CHRISTINE BREFEL COURBON | Contact (sur clinicalTrials) | |||
Chu Limoges - Limoges - France | JEAN-LUC HOUETO | Contact (sur clinicalTrials) | |||
Hopital Gabriel Montpied - Clermont-Ferrand - France | ANA MARQUES | Contact (sur clinicalTrials) |
Critères
Tous
Inclusion Criteria:
- Parkinson's disease patients as defined by the United Kingdom Parkinson's disease
Brain Bank (UKPDSBB) criteria and aged from 40 to 75 years old (included)
- Patients with motor fluctuations and/or invalidating dyskinesia and awaiting CSAI
establishment in the context of their usual care for PD
- Patients affiliated to a social security system
- Parkinson's disease patients as defined by the United Kingdom Parkinson's disease
Brain Bank (UKPDSBB) criteria and aged from 40 to 75 years old (included)
- Patients with motor fluctuations and/or invalidating dyskinesia and awaiting CSAI
establishment in the context of their usual care for PD
- Patients affiliated to a social security system
- Patients presenting an atypical parkinsonian syndrome Patients having a Deep Brain
Stimulation
- Patients with a psychiatric disease such as bipolar disorder or delusions linked to
a dopaminergic psychosis
- Patients presenting a cognitive deficit attested by a score to the Montreal
Cognitive Assessment inferior to 24, solely during the inclusion (baseline - V0)
- Patient with a serious pathology (e.g. cancer) or a health condition which could
interfere with the assessment of their quality of life, at the discretion of the
investigator upon inclusion
- Patients under guardianship, curatorship or safeguard of justice
- Patients under exclusion period from another study